, especially hyperuricaemia and hyperkalaemia, and (b) septic complications of 'debulking' surgery carried out before referral to our unit (Al-Attar et al., 1986) . In this study, BL II, we used the same GRAB chemotherapy, but discouraged debulking abdominal surgery and paid close attention to metabolic complications during the first two weeks of treatment. The objective was to determine whether, with this approach, we could further improve survival.
Patients and methods
Between May 1985 and November 1986, 24 consecutively diagnosed and previously untreated children with stages II, III and IV Burkitt lymphoma admitted to the paediatric oncology unit of Medical City Hospital were entered on the BL II study. Clinical details are given in Table I . There were' 19 boys and five girls (M:F 3.8:1), aged from 2 to 13 years, (median 5.4 years). The nutritional status of several children, as in BL I, was poor. The diagnosis was made by histopathological criteria in 22 cases (six biopsies of jaw tumours and 16 open biopsies of abdominal tumours) and in the remaining two by recognition of characteristic L-3 blasts (Bennett et al., 1976) Before each treatment course, as in BL I, the children were examined clinically to assess tumour response and blood count and renal/liver function tests were performed. Single site bone marrow aspirate was carried out every 8 weeks and CSF cell count and cytology after each of six serial lumbar punctures. Every 2 months after completion of chemotherapy, patients were examined clinically and underwent single site marrow aspiration plus trephine biopsy and CSF examination. Chest X-rays and intravenous urograms were repeated at 6 months off treatment. Thereafter patients were monitored regularly but only with clinical examination.
Three children had stage II tumours and 14 stage III (Table I) . Each of the seven stage IV patients had bone marrow involvement; one of them (case 5) also presented with acute bilateral visual loss, attributed to optic nerve infiltration by lymphoma, but this child and the six others had normal CSF at the time of diagnosis. Five children, including one with stage IV disease, had liver involvement and in three there were ovarian masses. Other sites of disease are noted in Table I .
Treatment, toxicity and survival Two children (cases 1 and 9) had 'debulking' surgery before referral to our unit. All children received the GRAB regime, exactly as described in Al-Attar et al. (1986) . There was no radiotherapy. Two patients (cases 13 and 17) died from complications of the tumour lysis syndrome (Lynch et al., 1977) , within one week of receiving the first course ('CHOP') in the GRAB regime. Thereafter, treatment was well tolerated and usually administered as an outpatient. Two children 
Discussion
In comparison with our prior experience, we were moderately satisfied with the results of BLI, especially since patients with overt stage IV disease were included. However, we felt that the early mortality could be reduced by more careful attention to supportive care during the first two weeks of therapy, when our patients' poor nutritional status (Al-Attar et al., 1986) was compounded by urate nephropathy and other biochemical effects of the 'tumour lysis syndrome'. In addition, a number of children had had early, and possibly unnecessary, 'debulking' surgery before transfer to our unit: before BL study II we encouraged our surgical colleagues to refer patients to us before laparotomy -a policy adhered to in 22/24 cases. The benefits of this policy are shown in Table II . In BL II, there were only two (8%) 'early' (and possibly avoidable) deaths compared with eight (33%) in BL I. The majority of relapses after therapy for advanced Burkitt lymphoma occur within 12 months from diagnosis, so we hope the majority of survivors in BL II have been cured. At least one previous study (Ziegler, 1977) has suggested a survival advantage for patients with BL undergoing initial debulking surgery. However, the chemotherapy used in that study was less intensive than ours. In our experience initial adjuvant surgery, especially in patients in poor general condition, may actually be a disadvantage because (a) it increases the risk of complications, especially sepsis, (b) it invariably delays the start of chemotherapy and (c) surgeons are tempted to remove organs, such as the uterus and ovaries, that are involved by tumour. In fact, two girl survivors of BL I underwent bilateral salpingo-oophorectomy and a boy developed a faecal fistula before referral to us: castration of the girls would almost certainly have been avoided if chemotherapy had been used first. Although a randomised study, with 'quality of survival' as well as 'survival' as end-points, would be needed to prove the point beyond doubt, we now discourage debulking surgery in our unit.
In 'developed' countries, the prognosis for stage IV chemotherapy is given (Anderson et al., 1983; Magrath et Months from diagnosis al., 1984) . Even with more toxic, prolonged, labour-intensive and expensive regimes (Murphy et al., 1986; Philip et al. , Figure 1 Actuarial event-free survival in study BL II (n = 24). (Anonymous, 1977) and solid tumours (Tucker et al., 1987) . In fact, one child in study BL I developed a tibial Ewing's sarcoma 4.5 years after completion of GRAB. Its oncogenicity, as well as its sterilising potential -particularly in boys, who outnumber girls 3:1 in most Burkitt series -are potent reasons for trying to eliminate cyclophosphamide from treatment schedules, particularly those for 'good risk' patients.
We have confirmed that a majority of Iraqi patients with advanced Burkitt lymphoma achieve complete remission with the GRAB regimen, without radiotherapy. It is likely that most patients attaining complete remission will be long-term survivors. The omission of debulking abdominal surgery has not apparently prejudiced disease-free survival and has probably contributed to the improved results seen in this study, compared with BL I. We are now directing our attention towards identification of a 'low risk' group of children in whom treatment can be refined and a 'high risk' group in whom treatment should be intensified. Initially we plan to investigate, for high risk patients, the so-called 'MACHO' schedule (I.M. Hann et al., unpublished observations) which incorporates high dose systemic cytosine arabinoside and methotrexate as well as triple intrathecal chemotherapy. For low risk patients, the elimination of cyclophosphamide from the GRAB schedule seems a worthwhile goal. We have already commenced pilot studies of 'HOP-GRAB' (GRAB) minus cyclophosphamide) in London.
